Adaptive Biotechnologies posts Q3 profitability, raises full-year MRD revenue guidance

Adaptive Biotechnologies Corporation reported financial results for the quarter ended September 30, 2026 on November 4, 2026. The company achieved total company profitability in the third quarter of 2026 with adjusted EBITDA of $14.3 million and free cash flow of $7.7 million.¹

Adaptive delivered 39,587 clonoSEQ tests in the third quarter of 2026, an increase of 46% versus the third quarter of 2025.¹ Total revenue was $83.9 million for the quarter, with MRD revenue increasing 28%, or 44% excluding milestones, versus the third quarter of 2025.¹

On the regulatory and guidelines front, Adaptive submitted a technical assessment to MolDX seeking an additional Medicare bundle for maintenance testing in multiple myeloma.¹ Separately, NCCN Guidelines established a dedicated framework for MRD assessment in multiple myeloma, including annual testing during maintenance,¹ and the International Myeloma Working Group introduced the first definition of cure for multiple myeloma, requiring a five-year treatment-free period with sustained MRD negativity assessed at a sensitivity of one myeloma cell among one million cells.¹

The company also noted it recognized revenue from successful data delivery under its target discovery agreement and is progressing with the Immune Medicine separation process.¹

On guidance, Adaptive raised full year 2026 MRD revenue guidance to a range of $276 million to $286 million, representing annual growth of 30% to 35%.¹ It expects full year total company operating expenses, including cost of revenue, to be approximately $350 million, updated from the previous range between $350 million and $355 million.¹

On cash position, cash, cash equivalents and marketable securities totaled $400.2 million as of September 30, 2026, inclusive of $13.8 million held by Digital Biotechnologies, Inc.¹